“Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Attention Deficit Hyperactivity Disorder Market.
The Attention Deficit Hyperactivity Disorder (ADHD) Pipeline report embraces in-depth commercial, regulatory, and Attention Deficit Hyperactivity Disorder clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Attention Deficit Hyperactivity Disorder drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for Attention Deficit Hyperactivity Disorder treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different Attention Deficit Hyperactivity Disorder therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the major Attention Deficit Hyperactivity Disorder companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the Attention Deficit Hyperactivity Disorder drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Attention Deficit Hyperactivity Disorder therapeutic market.
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Landscape
Attention-Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental condition associated with impaired function and increased risk of poor outcomes in children, young people, and adults with the condition.
Currently, approved pharmacological treatments for ADHD include a range of stimulant (methylphenidate, amphetamine) and non stimulant (atomoxetine, guanfacine, clonidine) medications. All have been shown to be effective in treating the symptoms of ADHD and improving other functional outcomes, including quality of life, academic performance, rates of accidents, and injuries, and do not appear to be associated with significant adverse outcomes or side effects.
These medicines are not a permanent cure for ADHD but may help someone with the condition concentrate better, be less impulsive, feel calmer, and learn and practice new skills. Some medicines need to be taken every day, but some can be taken just on school days. Treatment breaks are occasionally recommended, to assess whether the medicine is still needed.
There are approx. 20+ key companies developing therapies for Attention Deficit Hyperactivity Disorder. Currently, Otsuka Pharmaceutical is leading the therapeutics market with its Attention Deficit Hyperactivity Disorder drug candidates in the most advanced stage of clinical development.
Attention Deficit Hyperactivity Disorder (ADHD) Companies Actively Working in the Therapeutic Market Include:
3Z ehf Pharmaceuticals, ABVC BioPharma, AgoneX Biopharmaceuticals, Arbor Pharmaceuticals, BioLite, Inc., Cennerv Pharma, Cingulate, Curemark, Ensysce Biosciences, EnvisionRx, INVENT Pharmaceuticals, KemPharm, Materia Medica Holding, NeuroNascent, Inc., NLS Pharmaceutics Ltd, Otsuka Pharmaceutical, RespireRx Pharmaceuticals, Supernus Pharmaceuticals, Tris Pharma, Inc., and many others.
Emerging and Marketed Attention Deficit Hyperactivity Disorder (ADHD) Drugs Covered in the Report Include:
-
PDC-142: BioLite, Inc.
-
Dasotraline: Sunovion
-
ORADUR-Methylphenidate: Orient Pharma
-
Centanafadine: Otsuka Pharmaceutical
-
SHP465: Shire
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Attention Deficit Hyperactivity Disorder Companies Working in the Market @
Analysis of Emerging Attention Deficit Hyperactivity Disorder Therapies by Phases
The report covers the emerging products under different phases of clinical development like -
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Route of Administration
Attention Deficit Hyperactivity Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Intravenous
-
Subcutaneous
-
Parenteral
-
Topical
Molecule Type
Products have been categorized under various Molecule types such as
Recombinant fusion proteins
-
Small molecule
-
Monoclonal antibody
-
Peptide
-
Polymer
-
Gene therapy
Learn How the Attention Deficit Hyperactivity Disorder Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Attention Deficit Hyperactivity Disorder Treatment Patterns
4. Attention Deficit Hyperactivity Disorder - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Attention Deficit Hyperactivity Disorder Late Stage Products (Phase-III)
7. Attention Deficit Hyperactivity Disorder Mid-Stage Products (Phase-II)
8. Attention Deficit Hyperactivity Disorder Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Attention Deficit Hyperactivity Disorder Discontinued Products
13. Attention Deficit Hyperactivity Disorder Product Profiles
14. Major Attention Deficit Hyperactivity Disorder Companies in the Market
15. Key Products in the Attention Deficit Hyperactivity Disorder Therapeutics Segment
16. Dormant and Discontinued Products
17. Attention Deficit Hyperactivity Disorder Unmet Needs
18. Attention Deficit Hyperactivity Disorder Future Perspectives
19. Attention Deficit Hyperactivity Disorder Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
"Dysmenorrhea Market Insights, Epidemiology, and Market Forecast-2032" report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Dysmenorrhea market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Dysmenorrhea market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology
